Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Targovax ASA ( (GB:0RIS) ) has issued an update.
Circio Holding ASA has announced the registration of an increase in share capital with the Norwegian Register of Business Enterprises following the conversion of convertible bonds by Atlas Special Opportunities, LLC. This development highlights the company’s strategic financial activities, potentially strengthening its market position as it continues its innovative work in RNA therapeutics and cancer vaccines.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing next-generation RNA therapeutics and immunotherapy medicines. It has a proprietary circular RNA expression platform, called circVec technology, which enhances protein expression for genetic medicine applications. The company is also advancing a pan-RAS cancer vaccine, TG01, in clinical trials for various cancers, supported by collaborative networks and research grants.
YTD Price Performance: 0.04%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: NOK55.28M
For an in-depth examination of 0RIS stock, go to TipRanks’ Stock Analysis page.
